Neuroleptic malignant syndrome under treatment with antidepressants;Malignes neuroleptisches Syndrom unter der Behandlung mit Antidepressiva

Fortschritte der Neurologie Psychiatrie

Volumn 65, Issue 5, 1997, Pages 208-213

  Heinemann, F ^a,d   Assion, H J ^b   Laux, G ^c  

^a Abteilung Innere Medizin   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c Bezirkskrankenhaus Gabersee   (Germany)

^d St Josef Krankenhaus Moers GmbH Moers   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BROMOCRIPTINE; CHLORPROMAZINE; CLOMIPRAMINE; DANTROLENE; DESIPRAMINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; DOSULEPIN; FLUOXETINE; HALOPERIDOL; IMIPRAMINE; NEUROLEPTIC AGENT; PAROXETINE; THIORIDAZINE;

ARTICLE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEUROLEPTIC MALIGNANT SYNDROME; ORAL DRUG ADMINISTRATION; REVIEW;

EID: 0030979878     PISSN: 07204299     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-996323     Document Type: Article

References (34)

1. Addonizio, G., V. L. Susman, S. D. Roth: Neuroleptic malignant syndrome: Review and analysis of 115 cases. Biol. Psychiat. 22 (1987) 1004 - 1020
2. Ansseau, M., C. F. Reynolds, D. J. Kupfer: Central dopaminergic and noradrenergic receptor blockade in a patient with neuroleptic malignant syndrome. J. Clin. Psychiat. 47 (1986) 320 - 321
3. Assion, H. J., F. Heinemann, G. Laux: Antidepressants and Neuroleptic Malignant Syndrome. European Neuropsychopharmacology 5 (1995) 293
4. Baca, L., L. Martinelli: Neuroleptic malignant syndrome: a unique association with a tricyclic antidepressant. Neurology 40 (1990) 1797 - 1798
5. Baldessarini, R. J., E. Marsh: Fluoxetine and Side Effects. Arch. Gen. Psychiat. 47 (1990) 191 - 192
6. Benkert, O., H. Hippius: Psychiatrische Pharmakotherapie. 6. Auflage, Springer, Berlin, Heidelberg, New York 1996
7. Bouchard, R. H., E. Pourcher, P. Vincent: Fluoxetine and Extrapyramidal Side Effects. Am. J. Psychiat. 146 (1989) 1352 - 1353
8. Brod, T. M.: Fluoxetine and extrapyramidal side effects. Am. J. Psychiat. 146 (1989) 1353
9. Carter, C. J., C. J. Pycock: Possible importance of 5-hydroxytryptamine in neuroleptic-induced catalepsy in rats. Brit. J. Pharmacol. 60 (1977) 267 - 268
10. Corrigan, F. M., F. Coulter: Neuroleptic Malignant Syndrome, Amitriptyline, and Thioridazine. Biol. Psychiat. 23 (1988) 317 - 323
11. th ed. American Psychiatric Association. Washington, DC 1994
12. Delay, J., P. Deniker: Drug-induced extrapyramidal syndromes. In: Vinken, P. J., G. W. Bruyn (eds.): Handbook of clinical neurology, diseases of the basal ganglia 6 (1968) 248 - 266
13. De Maio, D., M. Laviani: Lithium-TCA induced malignant syndrome case report. Prog. Neuro. Psychopharmacol. Biol. Psychiat. 15 (o.J.) 427 - 431
14. Eiser, A. R., M. S. Neff, R. F. Slifkin: Acute myoglobinuric renal failure, a consequence of the neuroleptic malignant syndrome. Arch. Intern. Med. 142 (1982) 601 - 603
15. Fava, S., A. C. Galizia: Neuroleptic malignant syndrome and lithium carbonate. J. Psychiat. Neurosci. 20 (1995) 305 - 306
16. Garvey, M. J., G. D. Tollefson: Occurence of myoclonus in patients treated with cyclic antidepressants. Arch. Gen. Psychiat. 44 (1987) 269 - 272
17. Grant, R.: Neuroleptic malignant syndrome. Brit. Med. J. 288 (1984) 1690
18. Grohmann, R., E. Ruther: Neuroleptika. In: Grohmann, R., E. Rüther, L. G. Schmidt: Unerwünschte Wirkungen von Psychopharmaka. Ergebnisse der AMUP-Studie. Springer, Berlin, Heidelberg, New York o.J.
19. Halman, M., D. S. Goldbloom: Fluoxetine and Neuroleptic Malignant Syndrome. Biol. Psychiat. 28 (1990) 518 - 521
20. Heinemann, F., H. J. Assion: Serotonin uptake inhibitors and neuroleptic malignant syndrome. Pharmacopsychiatry 28 (1995) 186
21. Korsgaard, S., J. Gerlach, E. Christensson: Behavioural aspects of serotonin-dopamine interaction in the monkey. Europ. J. Pharmacol. 118 (1985) 245 - 252
22. Lee, H. K.: Dystonic reactions to amitriptyline and doxepin (letter). Am. J. Psychiat 145 (1988) 649
23. Levenson, J. L.: Neuroleptic malignant syndrome. Am. J. Psychiat 142 (1985) 1137 - 1145
24. Meltzer, H., M. Young, J. Metz et al.: Extrapyramidal side effects and increased serum prolactine following fluoxetine, a new antidepressant. J. Neural. Transm. 45 (1979) 165 - 175
25. Merriam, A. E.: Neuroleptic Malignant Syndrome After Imipramine Withdrawal. J. Clin. Psychopharmacol. 7 (1987) 53 - 54
26. Nisijima, K., T. Ishiguro: Does Dantrolene Influence Central Dopamine and Serotonin Metabolism in the Neuroleptic Malignant Syndrome? A Retrospective study. Biol. Psychiat. 33 (1993) 45 - 48
27. Pach, J.: Pharmakotoxische Psychose und extrapyramidalmotorisches Syndrom. Nervenarzt 63 (1992) 575 - 576
28. Pope, H. G., P. E. Keck, S. L. McElroy: Frequence and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am. J. Psychiatry 143 (1986) 1227 - 1233
29. Pietzcker, A.: Das maligne neuroleptische Syndrom. Nervenarzt 59 (1988) 691 - 700
30. Riederer, P., G. Laux, W. Pöldinger: Neuro-Psychopharmaka, Bd. 6. Springer, Wien, New York 1992
31. Rosebush, P., T. Stuart: A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am. J. Psychiat. 146 (1989) 717 - 725
32. Schibuk, M., D. Schachter: A role for catecholamines in the pathogenesis of neuroleptic malignant syndrome. Can. J. Psychiat 31 (1986) 66 - 69
33. Tate, J. L.: Extrapyramidal Symptoms in a Patient Taking Haloperidol and Fluoxetine. Am. J. Psychiat. 146 (1989) 399 - 400
34. Weller, M., J. Kornhuber: Pathophysiologie und Therapie des malignen neuroleptischen Syndroms. Nervenarzt 63 (1992) 645 - 655